Witnessing the stock’s movement on the chart, on Wednesday, Exact Sciences Corp. (NASDAQ: EXAS) had a quiet start as it plunged -0.89% to $73.60, before settling in for the price of $74.26 at the close. Taking a more long-term approach, EXAS posted a 52-week range of $56.05-$100.77.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
The Healthcare Sector giants’ yearly sales growth during the last 5-year period was 43.88%. Meanwhile, its Annual Earning per share during the time was 4.59%. Nevertheless, stock’s Earnings Per Share (EPS) this year is 21.81%. This publicly-traded company’s shares outstanding now amounts to $181.36 million, simultaneously with a float of $179.65 million. The organization now has a market capitalization sitting at $13.36 billion. At the time of writing, stock’s 50-day Moving Average stood at $62.97, while the 200-day Moving Average is $71.90.
Exact Sciences Corp. (EXAS) Ownership Facts and Figures
Nothing is more important than checking the behaviour of major investors towards the stock of the Diagnostics & Research industry. Exact Sciences Corp.’s current insider ownership accounts for 1.04%, in contrast to 90.13% institutional ownership. According to the most recent insider trade that took place on Apr 02 ’24, this organization’s EVP, GM., Precision Oncology sold 924 shares at the rate of 79.43, making the entire transaction reach 73,393 in total value, affecting insider ownership by 13,171. Preceding that transaction, on Apr 01 ’24, Company’s EVP, Human Resources sold 2,000 for 70.00, making the whole transaction’s value amount to 140,000. This particular insider is now the holder of 71,787 in total.
Exact Sciences Corp. (EXAS) Earnings and Revenue Records
As on 12/30/2023, Multinational firm has announced its last quarter scores, in which it reported -$0.27 earnings per share (EPS) for the period topping the consensus outlook (set at -$0.46) by $0.19. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.23 per share during the current fiscal year.
Exact Sciences Corp.’s EPS increase for this current 12-month fiscal period is 21.81% and is forecasted to reach 0.12 in the upcoming year.
Exact Sciences Corp. (NASDAQ: EXAS) Trading Performance Indicators
Let’s observe the current performance indicators for Exact Sciences Corp. (EXAS). It’s Quick Ratio in the last reported quarter now stands at 2.07. The Stock has managed to achieve an average true range (ATR) of 3.07. Another valuable indicator worth pondering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 5.34. Similarly, its price to free cash flow for trailing twelve months is now 418.43.
In the same vein, EXAS’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -1.14, a figure that is expected to reach -0.48 in the next quarter, and analysts are predicting that it will be 0.12 at the market close of one year from today.
Technical Analysis of Exact Sciences Corp. (EXAS)
Going through the that latest performance of [Exact Sciences Corp., EXAS]. Its last 5-days volume of 2.41 million indicated improvement to the volume of 2.25 million it revealed a year ago. During the previous 9 days, stock’s Stochastic %D was recorded 54.59% While, its Average True Range was 3.16.
Raw Stochastic average of Exact Sciences Corp. (EXAS) in the period of the previous 100 days is set at 74.46%, which indicates a major rise in contrast to 68.92% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 35.07% that was lower than 44.46% volatility it exhibited in the past 100-days period.
